Efficacy and effectiveness of SARS-CoV-2 vaccines for death prevention: A protocol for a systematic review and meta-analysis

• Published in: PloS one Vol. 17; no. 7; p. e0265414
• Main Authors: Trajman, Anete, Lachapelle-Chisholm, Sophie, Zikos, Théodora, Werneck, Guilherme Loureiro, Benedetti, Andrea
• Format: Journal Article
• Language: English
• Published: San Francisco Public Library of Science 28.07.2022; Public Library of Science (PLoS)
• Subjects: Bias; Biology and life sciences; Clinical trials; COVID-19; Design; Effectiveness; Fatalities; Health risks; Heterogeneity; Immunization; Inspection; Medical research; Medicine and health sciences; Meta-analysis; Mortality; Observational studies; Quality assessment; Research and Analysis Methods; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Statistical analysis; Statistical tests; Study Protocol; Vaccines; Brazil; India
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0265414

There is consistent evidence that SARS-CoV-2 vaccines have statistical and clinical significant efficacy to prevent incident and severe cases of COVID-19, although different outcomes were analyzed and different risk reductions were observed. However, randomized control trials (RCT) were not designed or powered to assess whether the vaccines prevent deaths, even though this was a secondary or exploratory outcome across many studies. Early real-world observational data suggest that these vaccines are highly effective in reducing hospitalization and all-cause mortality. Our objective is to summarize and appraise-the existing evidence on the efficacy and real-world effectiveness of all SARS-CoV-2 vaccines currently approved for full or limited use to prevent all-cause and COVID-19-attributed mortality. The population consists of persons with a record of vaccination status and the outcome of interest. Randomized controlled trials, comparative cohort and case-control studies reporting vaccination with any of the vaccines approved (intervention) will be eligible. The primary outcome will be all cause deaths. COVID-19-attributed deaths and deaths attributable to the vaccination (adverse event deaths) will be secondary outcomes. We will compare deaths occurring in vaccinated persons versus those non-vaccinated or having received placebo. Studies in any language will be eligible. Two independent reviewers will screen for inclusion and assess quality of studies using the Cochrane Risk of Bias 2 and the ROBINS-1 tool, as appropriate. Hazard ratios will be calculated. Assessment of statistical heterogeneity amongst the studies will be done using I.sup.2 and prediction intervals, as well as visual inspection of the forest plots. Publication bias will be assessed using a funnel plot and Egger statistical test if we have more than 10 studies in a forest plot. We have followed the PRISMA-Protocol checklist for the current protocol, which is registered at Prospero (York University, CRD42021262211).